ArticleBMC cancer2026
Multi-omics profiling highlights RPLP0 as a potential biomarker for prognosis and response to immunotherapy in clear cell renal cell carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is characterized by intratumoral heterogeneity and a complex immune microenvironment, which contribute to disease progression and therapeutic resistance. Although ribosomal proteins have been implicated in tumor biology, the clinical relevance, microenvironmental impact, and biological role of ribosomal protein lateral stalk subunit P0 (RPLP0) in ccRCC remain unclear.
methodsWe performed a comprehensive investigation integrating bulk transcriptomics (TCGA, GEO, ICGC, ArrayExpress), proteomics (CPTAC, HPA), single-cell RNA sequencing, and spatial transcriptomics to characterize RPLP0 expression, prognostic value, immunological relevance, and spatial distribution in ccRCC. The biological functions of RPLP0 were validated experimentally using clinical tissues (qRT-PCR, immunofluorescence) and ccRCC cell lines. Proliferation, migration, and invasion were assessed via CCK-8, wound healing, and Transwell assays following siRNA-mediated knockdown, with epithelial-mesenchymal transition (EMT) markers evaluated by Western blot.
resultsRPLP0 was ubiquitously expressed in normal tissues but significantly upregulated in ccRCC at both the mRNA and protein levels, which was validated in clinical specimens and cell lines. High RPLP0 expression was associated with advanced tumor stage, metastasis, and poor clinical outcomes, and was identified as an independent prognostic factor. Functional enrichment analyses revealed that RPLP0 was closely linked to ribosome-related processes, DNA damage response, cell cycle regulation, and epithelial-mesenchymal transition. Immune analyses demonstrated that elevated RPLP0 expression correlated with M2 macrophages, as well as with enhanced expression of immune checkpoint and antigen presentation-related genes. Single-cell and spatial transcriptomic analyses revealed the preferential enrichment of RPLP0 in the malignant compartment, with spatial transcriptomics further demonstrating a positive correlation with macrophages. Drug sensitivity analyses based on pRRophetic predictions showed that RPLP0-high tumors were associated with higher estimated IC50 values for several targeted therapies, suggesting a potential association between elevated RPLP0 expression and predicted reduced drug sensitivity. Mechanistically, RPLP0 knockdown in vitro significantly inhibited ccRCC cell proliferation, migration, and invasion, and reversed EMT progression by downregulating mesenchymal markers and upregulating the epithelial marker.
conclusionsThese findings indicate that RPLP0 is aberrantly upregulated in ccRCC, promoting tumor progression, migration, and invasion by facilitating the EMT process. Furthermore, its close association with immune activation and spatial heterogeneity highlights its potential as a robust prognostic biomarker and a regulator of tumor-microenvironment interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.